Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer
NCT03470350 · The Netherlands Cancer Institute · PHASE1/PHASE2 · withdrawn · last registry update 2019-07-24 · Colorectal cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No study drug available. Same concept with new study drug will be explored in M19TGA study” | Open Targets' class: logistics resources, study design | Registry record, The Netherlands Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TGFBR1 in colorectal cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision